

REMARKS

Claims 48, 50-55, 68, and 70-75 are active in this application. Claims 48 and 56 have been amended to define the transactivating factor as the HIV tat transactivating factor. This amendment is supported by Claim 49, Claim 57, and the specification page 4, lines 24-27. No new matter is added by these amendments.

Applicants wish to thank Examiner Priebe for indicating that Claims 48, 50-55, 68, and 70-75 would be allowable if the non-allowable claims were cancelled (Item 4 of the Advisory Action). As amended herein, Claims 48, 50-55, 68, and 70-75 are pending in this application. Therefore, Applicants request that this application be passed onto issuance.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

Daniel J. Pereira, Ph.D.
Registration No. 45,518

Customer Number
22850